Bevacizumab for ophthalmic diseases

被引：2

作者：

Michels, Stephan ^{[1
]}

Prager, Franz ^{[1
]}

Bakri, Sophie J. ^{[2
]}

Wacht, Joachim ^{[3
]}

机构：

[1] Med Univ Vienna, Gen Hosp Vienna, Dept Ophthalmol, Wahringer Gurtel 18-20, Vienna, Wien 1090, Austria

[2] Dept Ophthalmol, Rochester, MN 55905 USA

[3] Dept Ophthalmol, Berlin, Germany

来源：

EXPERT REVIEW OF OPHTHALMOLOGY | 2007年 / 2卷 / 03期

关键词：

AMD; angiogenesis; anti-VEGF; Avastin ((R)); bevacizumab; choroidal neovascularization; eye; macular degeneration; neovascularization; ocular; vascular endothelial growth factor;

D O I：

10.1586/17469899.2.3.369

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Bevacizumab, a humanized monoclonal antibody that binds to all isoforms of vascular endothelial growth factor, was originally developed to inhibit tumor angiogenesis. Following its approval for the treatment of metastatic colorectal cancer, bevacizumab was initially used systemically in patients with neovascular age-related macular degeneration. Two case reports on intravitreal bevacizumab led to numerous clinical and preclinical studies on bevacizumab. Intravitreal bevacizumab is popular worldwide as an inexpensive off-label treatment for several neovascular ocular diseases. This article reviews the current clinical and preclinical studies using bevacizumab in ophthalmology.

引用

页码：369 / 378

页数：10

共 50 条

[1] Ranibizumab versus Bevacizumab for Ophthalmic Diseases Related to Neovascularisation: A Meta-Analysis of Randomised Controlled Trials
Wu, Bin
Wu, Haixiang
Liu, Xiaoyan
Lin, Houwen
Li, Jin
PLOS ONE, 2014, 9 (07):
[2] Evaluation of the Performance of an Ophthalmic Thermosensitive Hydrogel Containing Combination of Suramin and Bevacizumab
Alejandra Quinteros, Daniela
Sebastian Lopez, Emiliano
Silva Couto, Juan Lucio
Angelica Maletto, Belkys
Alberto Allemandi, Daniel
Daniel Palma, Santiago
Eduardo Gallo, Juan
CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (43) : 6587 - 6594
[3] BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION RELATED TO INFLAMMATORY DISEASES
Kramer, Michal
Axer-Siegel, Ruth
Jaouni, Tareq
Reich, Ehud
Hemo, Itzhak
Priel, Ethan
Averbukh, Edward
Ehrlich, Rita
Chowers, Itay
Weinberger, Dov
Amer, Radgonde
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2010, 30 (06): : 938 - 944
[4] In Vitro Coagulation Effects of Ophthalmic Doses of Bevacizumab
Li, Emily
Greenberg, Paul B.
Tseng, Victoria
Woodmansee, Suzanne B.
Caffrey, Aisling R.
Wu, Wen-Chih
Friedmann, Peter D.
LaPlante, Kerry L.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2012, 28 (03) : 219 - 221
[5] Cellular senescence and ophthalmic diseases: narrative review
Soleimani, Mohammad
Cheraqpour, Kasra
Koganti, Raghuram
Djalilian, Ali R. R.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2023, 261 (11) : 3067 - 3082
[6] Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: A review
Bressler, Neil M.
Kaiser, Peter K.
Do, Diana, V
Nguyen, Quan Dong
Park, Kyu Hyung
Woo, Se Joon
Sagong, Min
Bradvica, Mario
Kim, Mercy Yeeun
Kim, Seungkee
Sadda, SriniVas R.
SURVEY OF OPHTHALMOLOGY, 2024, 69 (04) : 521 - 538
[7] Resveratrol and Ophthalmic Diseases
Abu-Amero, Khaled K.
Kondkar, Altaf A.
Chalam, Kakarla V.
NUTRIENTS, 2016, 8 (04)
[8] Genetic Isolates in Ophthalmic Diseases
Sherwin, Justin C.
Hewitt, Alex W.
Ruddle, Jonathan B.
Mackey, David A.
OPHTHALMIC GENETICS, 2008, 29 (04) : 149 - 161
[9] Chitosan-Polycaprolactone Core-Shell Microparticles for Sustained Delivery of Bevacizumab
Jiang, Pengfei
Jacobs, Kane M.
Ohr, Matthew P.
Swindle-Reilly, Katelyn E.
MOLECULAR PHARMACEUTICS, 2020, 17 (07) : 2570 - 2584
[10] Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells
Carneiro, Angela
Falcao, Manuel
Pirraco, Ana
Milheiro-Oliveira, Paula
Falcao-Reis, Fernando
Soares, Raquel
EXPERIMENTAL EYE RESEARCH, 2009, 88 (03) : 522 - 527

← 1 2 3 4 5 →